Diabetes is one of the most urgent healthcare challenges that we are currently facing, and there is a growing need for medications which can manage the condition on a long-term basis. Researchers at Stockholm University working with startup Atrogi AB have developed a novel approach which targets the β₂ adrenergic receptors, circumventing the failing insulin signaling pathway. This unique way of addressing the problem potentially opens the way to a new class of diabetes medications.

中文翻译：

---

一种治疗 2 型糖尿病的新方法——靶向非胰岛素依赖途径

糖尿病是我们目前面临的最紧迫的医疗保健挑战之一，对能够长期控制病情的药物的需求不断增长。斯德哥尔摩大学的研究人员与初创公司 Atrogi AB 合作开发了一种针对 β2 肾上腺素能受体的新方法，从而_绕过了失败的胰岛素信号通路。这种解决问题的独特方法可能为新型糖尿病药物开辟道路。